PROPHETIC Extended - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Extended Study.
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Provision of informed consent prior to any study-specific procedures.
• Male or female aged at least 18 years.
• ECOG PS - 0/1-2.
Locations
United States
Texas
Baylor Scott and White Research Institute
RECRUITING
Dallas
Contact Information
Primary
Galit Yahalom, PhD
galit@oncohost.com
97248537557
Backup
Shani Raveh Shoval, PhD
shani@oncohost.com
97248537557
Time Frame
Start Date: 2022-11-07
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 350
Treatments
Non-operable NSCLC patients receiving ICI therapy
Patients with non-operable stage IIIB-IV NSCLC treated with immune check inhibitor anti cancer treatment as a standard of care
Operable NSCLC Patients Receiving ICI as Neoadjuvant or Adjuvant Therapy
Patients with operable stage II-IIIA NSCLC, treated with immune check inhibitor in the neoadjuvant or adjuvant setting
Healthy volunteers
Sex and aged matched non-diseased volunteers
Related Therapeutic Areas
Sponsors
Leads: OncoHost Ltd.